Hahn Capital Management LLC Lowers Holdings in Labcorp Holdings Inc. $LH

Hahn Capital Management LLC reduced its stake in Labcorp Holdings Inc. (NYSE:LH) by 1.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 34,596 shares of the medical research company’s stock after selling 525 shares during the period. Labcorp makes up approximately 4.3% of Hahn Capital Management LLC’s holdings, making the stock its 10th largest holding. Hahn Capital Management LLC’s holdings in Labcorp were worth $9,082,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of LH. Golden State Wealth Management LLC grew its stake in shares of Labcorp by 88.1% in the 1st quarter. Golden State Wealth Management LLC now owns 111 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 52 shares during the period. North Capital Inc. bought a new stake in shares of Labcorp in the 1st quarter valued at approximately $27,000. TruNorth Capital Management LLC bought a new stake in shares of Labcorp in the 1st quarter valued at approximately $28,000. Larson Financial Group LLC grew its stake in shares of Labcorp by 140.4% in the 1st quarter. Larson Financial Group LLC now owns 125 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 73 shares during the period. Finally, Financial Gravity Asset Management Inc. bought a new stake in shares of Labcorp in the 1st quarter valued at approximately $31,000. 95.94% of the stock is currently owned by institutional investors.

Labcorp Stock Down 0.0%

NYSE:LH opened at $279.02 on Friday. The company has a market cap of $23.19 billion, a price-to-earnings ratio of 30.80, a P/E/G ratio of 1.78 and a beta of 0.89. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.32 and a current ratio of 1.50. The stock’s fifty day moving average price is $273.46 and its two-hundred day moving average price is $254.18. Labcorp Holdings Inc. has a 52-week low of $209.38 and a 52-week high of $289.20.

Labcorp (NYSE:LH) last released its earnings results on Thursday, July 24th. The medical research company reported $4.35 EPS for the quarter, beating the consensus estimate of $4.14 by $0.21. The company had revenue of $3.53 billion during the quarter, compared to analysts’ expectations of $3.49 billion. Labcorp had a return on equity of 15.45% and a net margin of 5.66%.The business’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same period last year, the firm earned $3.94 EPS. Labcorp has set its FY 2025 guidance at 16.050-16.500 EPS. On average, analysts anticipate that Labcorp Holdings Inc. will post 16.01 EPS for the current year.

Labcorp Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, September 11th. Stockholders of record on Thursday, August 28th were paid a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend was Thursday, August 28th. Labcorp’s dividend payout ratio (DPR) is 31.79%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Robert W. Baird set a $311.00 price objective on Labcorp in a research note on Monday, August 25th. Hsbc Global Res downgraded Labcorp from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 10th. UBS Group boosted their target price on Labcorp from $282.00 to $305.00 and gave the stock a “buy” rating in a report on Friday, July 25th. Wall Street Zen raised Labcorp from a “hold” rating to a “buy” rating in a report on Saturday, July 26th. Finally, Morgan Stanley boosted their target price on Labcorp from $283.00 to $306.00 and gave the stock an “overweight” rating in a report on Friday, July 25th. Nine investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $291.58.

Insider Transactions at Labcorp

In other news, Director Dwight Gary Gilliland sold 2,000 shares of Labcorp stock in a transaction on Wednesday, July 30th. The stock was sold at an average price of $264.95, for a total value of $529,900.00. Following the completion of the sale, the director directly owned 6,656 shares of the company’s stock, valued at approximately $1,763,507.20. This trade represents a 23.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kerrii B. Anderson sold 3,500 shares of Labcorp stock in a transaction on Thursday, July 24th. The shares were sold at an average price of $280.00, for a total value of $980,000.00. Following the completion of the sale, the director directly owned 8,666 shares of the company’s stock, valued at $2,426,480. This trade represents a 28.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 15,046 shares of company stock valued at $4,074,692 over the last quarter. Corporate insiders own 0.84% of the company’s stock.

About Labcorp

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.